RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+10.77%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.58B
AUM Growth
+$4.58B
(-2.1%)
Cap. Flow
+$43.2M
Cap. Flow
% of AUM
0.94%
Top 10 Holdings %
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
20
Top Buys
| 1 |
Immunocore
IMCR
|
$97.6M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$73M |
| 3 |
Bolt Biotherapeutics
BOLT
|
$51.3M |
| 4 |
Cullinan Oncology
CGEM
|
$44.8M |
| 5 |
AstraZeneca
AZN
|
$32.3M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$54.5M |
| 2 |
UnitedHealth
UNH
|
$48.4M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$47.9M |
| 4 |
Centene
CNC
|
$43.8M |
| 5 |
Immunovant
IMVT
|
$41.2M |
Sector Composition
| 1 | Healthcare | 93.74% |
| 2 | Consumer Staples | 1.75% |
| 3 | Industrials | 0.62% |
| 4 | Financials | 0.12% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRRA
76
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $17.5M | 0.38% | 1,017,358 +450,000 | +79% | +$7.75M |
|
|
GMDA
77
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $17M | 0.37% | 2,100,300 +6,300 | +0.3% | +$51K |
|
|
INZY
78
DELISTED
Inozyme Pharma
INZY
| $16.4M | 0.36% | 827,900 -2,646 | -0.3% | -$52.4K |
|
79
Prelude Therapeutics
PRLD
$68.5M
| $16.4M | 0.36% | 378,195 +17,832 | +5% | +$773K |
|
80
Dynavax Technologies
DVAX
$1.19B
| $16.3M | 0.36% | 1,658,520 +9,100 | +0.6% | +$89.5K |
|
81
Rigel Pharmaceuticals
RIGL
$697M
| $16.2M | 0.35% | 4,742,000 -891 | -0% | -$3.05K |
|
82
Nkarta
NKTX
$151M
| $16.2M | 0.35% | 491,848 -49,152 | -9% | -$1.62M |
|
|
MREO
83
Mereo BioPharma
MREO
$272M
| $15.1M | 0.33% | +4,494,869 | New | +$15.1M |
|
84
Akero Therapeutics
AKRO
$3.74B
| $15.1M | 0.33% | 521,171 +5,800 | +1% | +$168K |
|
85
ESSA Pharma
EPIX
$11.4M
| $14.6M | 0.32% | +503,035 | New | +$14.6M |
|
86
Athira Pharma
ATHA
$15.3M
| $14.5M | 0.32% | 788,202 -72,700 | -8% | -$1.34M |
|
|
OLK
87
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $14.4M | 0.31% | +400,000 | New | +$14.4M |
|
88
Spero Therapeutics
SPRO
$116M
| $14.2M | 0.31% | 965,928 -269,072 | -22% | -$3.96M |
|
89
Theravance Biopharma
TBPH
$699M
| $13.9M | 0.3% | 682,600 +4,400 | +0.6% | +$89.8K |
|
|
CERE
90
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $13.8M | 0.3% | 1,005,100 +6,100 | +0.6% | +$83.8K |
|
91
Applied Therapeutics
APLT
$71M
| $13.2M | 0.29% | 701,680 +65,843 | +10% | +$1.23M |
|
92
TG Therapeutics
TGTX
$4.65B
| $12.8M | 0.28% | 266,520 -222,480 | -45% | -$10.7M |
|
93
Rhythm Pharmaceuticals
RYTM
$6.85B
| $12.7M | 0.28% | 599,280 +108,941 | +22% | +$2.32M |
|
94
Galapagos
GLPG
$2.07B
| $12.7M | 0.28% | 165,000 | – | – |
|
95
MacroGenics
MGNX
$112M
| $12.5M | 0.27% | 393,479 +83,969 | +27% | +$2.67M |
|
96
Spyre Therapeutics
SYRE
$996M
| $12.5M | 0.27% | 1,577,296 -2,704 | -0.2% | -$21.4K |
|
97
InnovAge Holding
INNV
$517M
| $12.3M | 0.27% | +475,000 | New | +$12.3M |
|
|
PRTK
98
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $11.9M | 0.26% | 1,684,714 +4,100 | +0.2% | +$28.9K |
|
99
Baxter International
BAX
$12.7B
| $11.8M | 0.26% | 140,000 -161,000 | -53% | -$13.6M |
|
100
AnaptysBio
ANAB
$569M
| $11.5M | 0.25% | 535,232 +225,819 | +73% | +$4.87M |
|